Viewing Study NCT05687058

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:26 AM
Ignite Modification Date: 2026-01-29 @ 1:30 AM
Study NCT ID: NCT05687058
Status: RECRUITING
Last Update Posted: 2025-06-25
First Post: 2022-09-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Empagliflozin in ESKD - A Feasibility Study
Sponsor: University of Mississippi Medical Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Kidney Failure, Chronic View
None Heart Failure View
Keywords:

Keywords

Keyword Brief Keyword Text View
None empagliflozin View
None end-stage kidney disease View
None pharmacokinetics View
None pharmacodynamics View
None feasibility trial View
None heart failure View
None residual kidney function View
None Sodium-glucose transporter type 2 inhibitor View